U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H3N2O4.K
Molecular Weight 194.1866
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POTASSIUM OROTATE

SMILES

[K+].[O-]C(=O)C1=CC(=O)NC(=O)N1

InChI

InChIKey=DHBUISJCVRMTAZ-UHFFFAOYSA-M
InChI=1S/C5H4N2O4.K/c8-3-1-2(4(9)10)6-5(11)7-3;/h1H,(H,9,10)(H2,6,7,8,11);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C5H3N2O4
Molecular Weight 155.0883
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Potassium Orotate is a non-steroidal anabolic preparation with regenerating, diuretic effect. Potassium Orotate improves appetite, cardiac glycosides tolerance, stimulates regenerative and reparative processes of metabolism. Orotic acid is one of precursors the pyrimidine nucleotides which are a part of nucleic acids which participate in synthesis of protein molecules. In this regard potassium orotate is applied as substance of anabolic action at disturbances of protein metabolism, first of all at disturbance of albumin function of a liver, at the dystrophic changes in a myocardium which developed as owing to pathological process (a myocarditis, myocardial infarction), and as a result of a physical overstrain in sport as the general stimulators of metabolic processes.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Potassium orotate

Approved Use

Potassium orotate is prescribed for diseases / conditions: Combined therapy includes ischemic heart disease (including myocardial infarction and angina pectoris), chronic heart failure and heart rhythm disturbances (including magnesium-dependent and ciliary arrhythmia); Alimentary-infection and alimentary dystrophy in children; Hyperlipidemia; Atherosclerosis; Anemia; As an auxiliary - diseases of the bile duct and liver (including hepatosis, hepatitis) caused by chronic and acute intoxication, except for organic lesions of the bile duct and liver; Spastic conditions (including angiospasm); Myocardial dystrophy; Progressive muscular dystrophy; Increased physical activity; Dermatoses.
Primary
Potassium orotate

Approved Use

Potassium orotate is prescribed for diseases / conditions: Combined therapy includes ischemic heart disease (including myocardial infarction and angina pectoris), chronic heart failure and heart rhythm disturbances (including magnesium-dependent and ciliary arrhythmia); Alimentary-infection and alimentary dystrophy in children; Hyperlipidemia; Atherosclerosis; Anemia; As an auxiliary - diseases of the bile duct and liver (including hepatosis, hepatitis) caused by chronic and acute intoxication, except for organic lesions of the bile duct and liver; Spastic conditions (including angiospasm); Myocardial dystrophy; Progressive muscular dystrophy; Increased physical activity; Dermatoses.
Primary
Potassium orotate

Approved Use

Potassium orotate is prescribed for diseases / conditions: Combined therapy includes ischemic heart disease (including myocardial infarction and angina pectoris), chronic heart failure and heart rhythm disturbances (including magnesium-dependent and ciliary arrhythmia); Alimentary-infection and alimentary dystrophy in children; Hyperlipidemia; Atherosclerosis; Anemia; As an auxiliary - diseases of the bile duct and liver (including hepatosis, hepatitis) caused by chronic and acute intoxication, except for organic lesions of the bile duct and liver; Spastic conditions (including angiospasm); Myocardial dystrophy; Progressive muscular dystrophy; Increased physical activity; Dermatoses.
Primary
Potassium orotate

Approved Use

Potassium orotate is prescribed for diseases / conditions: Combined therapy includes ischemic heart disease (including myocardial infarction and angina pectoris), chronic heart failure and heart rhythm disturbances (including magnesium-dependent and ciliary arrhythmia); Alimentary-infection and alimentary dystrophy in children; Hyperlipidemia; Atherosclerosis; Anemia; As an auxiliary - diseases of the bile duct and liver (including hepatosis, hepatitis) caused by chronic and acute intoxication, except for organic lesions of the bile duct and liver; Spastic conditions (including angiospasm); Myocardial dystrophy; Progressive muscular dystrophy; Increased physical activity; Dermatoses.
Primary
Potassium orotate

Approved Use

Potassium orotate is prescribed for diseases / conditions: Combined therapy includes ischemic heart disease (including myocardial infarction and angina pectoris), chronic heart failure and heart rhythm disturbances (including magnesium-dependent and ciliary arrhythmia); Alimentary-infection and alimentary dystrophy in children; Hyperlipidemia; Atherosclerosis; Anemia; As an auxiliary - diseases of the bile duct and liver (including hepatosis, hepatitis) caused by chronic and acute intoxication, except for organic lesions of the bile duct and liver; Spastic conditions (including angiospasm); Myocardial dystrophy; Progressive muscular dystrophy; Increased physical activity; Dermatoses.
PubMed

PubMed

TitleDatePubMed
[The treatment results in patients with gouty nephropathy].
1990 Jun
[Psychophysiological effects of combined administration of pantogam and potassium orotate in patients with neurotic disorders].
2001 May-Jun
[The influence of 'potassium orotate' on neocollagenogenesis in implantation of polypropylene endoprosthesis and polypropylene combined with polylactic acid endoprosthesis].
2017
Patents

Sample Use Guides

Potassium orotate taken internally 2-3 times a day for 250-500 mg. The drug is recommended to take 1 hour before meals or 4 hours after. Duration of therapy - 20-40 days, if necessary, the course can be repeated in a month. Children are usually prescribed 10-20 mg / kg per day, the frequency of reception is 2-3 times a day. The duration of the treatment course is 21-35 days.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:16:28 GMT 2023
Edited
by admin
on Fri Dec 15 15:16:28 GMT 2023
Record UNII
6ZDN9W1C9W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
POTASSIUM OROTATE
WHO-DD  
Common Name English
OROPUR K
Brand Name English
4-PYRIMIDINECARBOXYLIC ACID, 1,2,3,6-TETRAHYDRO-2,6-DIOXO-, POTASSIUM SALT (1:1)
Common Name English
DIORON
Brand Name English
BA-2658
Code English
4-PYRIMIDINECARBOXYLIC ACID, 1,2,3,6-TETRAHYDRO-2,6-DIOXO-, MONOPOTASSIUM SALT
Common Name English
BA 2658
Code English
Potassium orotate [WHO-DD]
Common Name English
OROTIC ACID POTASSIUM SALT
Common Name English
URACIL-4-CARBOXYLIC ACID POTASSIUM SALT
Common Name English
OROTIC ACID, MONOPOTASSIUM SALT
Common Name English
Code System Code Type Description
EVMPD
SUB14989MIG
Created by admin on Fri Dec 15 15:16:28 GMT 2023 , Edited by admin on Fri Dec 15 15:16:28 GMT 2023
PRIMARY
EPA CompTox
DTXSID0067004
Created by admin on Fri Dec 15 15:16:28 GMT 2023 , Edited by admin on Fri Dec 15 15:16:28 GMT 2023
PRIMARY
SMS_ID
100000078843
Created by admin on Fri Dec 15 15:16:28 GMT 2023 , Edited by admin on Fri Dec 15 15:16:28 GMT 2023
PRIMARY
PUBCHEM
23665705
Created by admin on Fri Dec 15 15:16:28 GMT 2023 , Edited by admin on Fri Dec 15 15:16:28 GMT 2023
PRIMARY
CAS
24598-73-0
Created by admin on Fri Dec 15 15:16:28 GMT 2023 , Edited by admin on Fri Dec 15 15:16:28 GMT 2023
PRIMARY
ECHA (EC/EINECS)
246-341-0
Created by admin on Fri Dec 15 15:16:28 GMT 2023 , Edited by admin on Fri Dec 15 15:16:28 GMT 2023
PRIMARY
RXCUI
8602
Created by admin on Fri Dec 15 15:16:28 GMT 2023 , Edited by admin on Fri Dec 15 15:16:28 GMT 2023
PRIMARY RxNorm
FDA UNII
6ZDN9W1C9W
Created by admin on Fri Dec 15 15:16:28 GMT 2023 , Edited by admin on Fri Dec 15 15:16:28 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE